Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion
Sponsors
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH, Region Sjaelland, Universitaetsklinikum Tuebingen AöR, Associazione Italiana Per Lo Studio Del Pancreas
Conditions
Colorectal cancerHER2 positive resectable esophagogastric adenocarcinomaMale and female patients with histologically confirmed diagnosis of rectal cancerRectum cancerT1-T2N0 esophageal adenocarcinoma including gastroesophageal
junction (GEJ) with indication for radical surgeryadvanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionslocally advanced resectable adenocarcinoma of the oesophagogastric
junction or the stomachpancreatic ductal adenocarcinoma
Phase 1
NEOadjuvant chemotherapy only compared with standard treatment for Locally Advanced Rectal cancer: a randomized phase II trial
Active, not recruitingCTIS2024-517748-76-00
Start: 2016-11-14Target: 124Updated: 2024-10-08
NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therapies for HER2+, resectable esophagogastric adenocarcinoma
RecruitingCTIS2024-518841-12-00
Start: 2025-03-25Target: 39Updated: 2025-12-01
Phase 2
The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group
RecruitingCTIS2024-512980-29-00
Start: 2023-08-28Target: 32Updated: 2025-10-22
DANTE / FLOT8
A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340)– The IKF-DANTE Trial
A Trial of AIO in collaboration with SAKK
Active, not recruitingCTIS2024-514945-12-00
Start: 2018-09-03Target: 624Updated: 2025-12-11
Organ preservation in locally advanced rectal cancer by
radiochemotherapy followed by consolidation chemotherapy. A
prospective phase II pilot trial of the German Rectal Cancer
Study Group
CompletedCTIS2024-517928-19-00
Start: 2018-04-17End: 2025-07-30Target: 89Updated: 2025-02-25
FUTURE platform trial –
A phase II platform trial of futibatinib in combination with (chemo)immunotherapy in colorectal cancer and other solid tumor entities
RecruitingCTIS2024-517573-24-00
Start: 2025-12-08Target: 33Updated: 2025-12-02
Phase 3
Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY
Active, not recruitingCTIS2024-512934-14-00
Start: 2016-11-07Target: 319Updated: 2025-06-23
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)
Not yet recruitingCTIS2024-519031-42-00
Target: 261Updated: 2024-11-18